Suppr超能文献

aro-沙门氏菌活疫苗赋予的免疫力。

Immunity conferred by Aro- Salmonella live vaccines.

作者信息

Hormaeche C E, Joysey H S, Desilva L, Izhar M, Stocker B A

机构信息

Department of Pathology, University of Cambridge, U.K.

出版信息

Microb Pathog. 1991 Feb;10(2):149-58. doi: 10.1016/0882-4010(91)90075-l.

Abstract

The specificity of protection conferred by Aro- salmonellae was studied in BALB/c mice challenged 3 months after intravenous (i.v.) vaccination, more than 1 month after the vaccine had been cleared. Oral challenge showed better protection than i.v. challenge. Salmonella typhimurium aroA SL3261 conferred very good protection against wild-type S. typhimurium C5 (over 10,000 x LD50). Cross protection experiments were performed using S. typhimurium, S. enteritidis and S. dublin for vaccination and challenge, including variants of S. typhimurium and S. enteritidis of similar virulence differing in the main LPS antigen (O-4 or O-9). Salmonella typhimurium aroA conferred solid protection against S. typhimurium (O-4), but no protection against wild-type S. enteritidis (O-9). However challenge with LPS variant strains showed that although protection was generally better to strains of the homologous LPS type, specificity of protection was determined more by the parent strain background (S. typhimurium or S. enteritidis) of the challenge than by O-factors 4 or 9, suggesting that other antigens are involved. The nature of the protective antigen(s) in this model is unclear, but it does not appear to be the main O-specific antigen. A S. enteritidis Se795 aroA vaccine gave good protection against wild-type S. enteritidis Se795 2 weeks after vaccination, but much less at 3 months (approximately 10-200 x LD50), although the persistence of the S. enteritidis aroA vaccine in the liver and spleen was similar to that of the S. typhimurium vaccine, and the wild-type Se795 challenge strain was of similar virulence to S. typhimurium C5. A S. dublin aroA vaccine conferred similar protection against wild-type S. dublin (approximately 300 x LD50).

摘要

在静脉注射(i.v.)疫苗接种3个月后、疫苗清除1个月以上对BALB/c小鼠进行攻毒,研究了aro-鼠伤寒沙门氏菌提供的保护特异性。口服攻毒显示出比静脉注射攻毒更好的保护效果。鼠伤寒沙门氏菌aroA SL3261对野生型鼠伤寒沙门氏菌C5具有非常好的保护作用(超过10,000倍LD50)。使用鼠伤寒沙门氏菌、肠炎沙门氏菌和都柏林沙门氏菌进行疫苗接种和攻毒的交叉保护实验,包括主要LPS抗原(O-4或O-9)不同但毒力相似的鼠伤寒沙门氏菌和肠炎沙门氏菌变体。鼠伤寒沙门氏菌aroA对鼠伤寒沙门氏菌(O-4)具有可靠的保护作用,但对野生型肠炎沙门氏菌(O-9)没有保护作用。然而,用LPS变异株进行攻毒表明,虽然对同源LPS类型的菌株保护通常更好,但保护的特异性更多地由攻毒株的亲本菌株背景(鼠伤寒沙门氏菌或肠炎沙门氏菌)决定,而不是由O因子4或9决定,这表明还有其他抗原参与其中。该模型中保护性抗原的性质尚不清楚,但似乎不是主要的O特异性抗原。肠炎沙门氏菌Se795 aroA疫苗在接种后2周对野生型肠炎沙门氏菌Se795具有良好的保护作用,但在3个月时保护作用要小得多(约10-200倍LD50),尽管肠炎沙门氏菌aroA疫苗在肝脏和脾脏中的持续存在情况与鼠伤寒沙门氏菌疫苗相似,且野生型Se795攻毒株的毒力与鼠伤寒沙门氏菌C5相似。都柏林沙门氏菌aroA疫苗对野生型都柏林沙门氏菌具有相似的保护作用(约300倍LD50)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验